Dideoxycytidine
Specifications
7481-89-2CAS Number
620-762-3EC Number
4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-oneIUPAC Name
C9H13N3O3Chemical Formula
211.22 g/molMolecular Weight
zalcitabine; Dideoxycytidine; 7481-89-2; 2',3'-DIDEOXYCYTIDINE; ddCyd; Cytidine, 2',3'-dideoxy-; 4-Amino-1-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; DTXSID0023747; NSC 606170; Ro 24-2027/000; Ro-24-2027/000; zalcitabina; 6L3XT8CB3I; NSC606170; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Ro-242027000; DTXCID703747; Ro-24-2027000; CHEBI:10101; Zalcitabine (dideoxycytidine,ddc); 4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; ddC (Antiviral); 4-AMINO-1-[(2R,5S)-5-(HYDROXYMETHYL)OXOLAN-2-YL]-1,2-DIHYDROPYRIMIDIN-2-ONE; HIVID Roche; 2',3' Dideoxycytidine; zalcitabinum; 4-amino-1-((2R,5S)-5-(hydroxymethyl)oxolan-2-yl)pyrimidin-2-one; 4-amino-1-((2R,5S)-5-(hydroxymethyl)oxolan-2-yl)-1,2-dihydropyrimidin-2-one; RefChem:389367; J05AF03; 620-762-3; HIVID; ddC; MFCD00012188; NSC-606170; 2', 3'-dideoxycytidine; CHEMBL853; NCGC00090705-08; Zalcitibine; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 2,3-dideoxycytidine; SMR000058253; CCRIS 692; Hivid(TM); Hivid (TN); HSDB 7156; ddC & GM-CSF; ddC & sCD4; PC-SOD & ddC; DDC (DDC); UNII-6L3XT8CB3I; BRN 0654956; Zalcitabine (JAN/USP/INN); Zalcitabine?; DS-4152 & ddC; 3-[(5S,2R)-5-(hydroxymethyl)oxolan-2-yl]-6-amino-3-hydropyrimidin-2-one; 1-(2,3-Dideoxy-beta-D-ribofuranosyl)cytosine; ddC & NP (from PHCA or HSA); SRI-7707; Zalcitabine [USAN:USP:INN:BAN]; 2',3'-Dideoxycytidine;ddC;Dideoxycytidine; CAS-7481-89-2; KS-1130; ddC & IFN.alpha.; .beta.-D-DDC; dideoxycytidine (DDC); Zalcitabine (Standard); ZALCITABINE [MI]; Prestwick0_001037; Prestwick1_001037; Prestwick2_001037; Prestwick3_001037; ddC & Interferon.alpha.; ZALCITABINE [INN]; ZALCITABINE [JAN]; ZALCITABINE [HSDB]; ZALCITABINE [IARC]; ZALCITABINE [USAN]; bmse000712; UPCMLD-DP115; D 5782; ZALCITABINE [VANDF]; SCHEMBL3598; TimTec1_004969; ZALCITABINE [MART.]; 2',3'-Dideoxy-D-cytidine; Lopac0_000360; BSPBio_001253; ZALCITABINE [USP-RS]; ZALCITABINE [WHO-DD]; 5-25-14-00313 (Beilstein Handbook Reference); MLS000069636; MLS000759540; MLS001055363; MLS001424210; MLS006011951; SPBio_003104; BPBio1_001378; GTPL4828; orb1224080; orb1310928; 2',3'-ddC; SCHEMBL10378805; UPCMLD-DP115:001; Zalcitabine - Bio-X trade mark; 2',3'-Dideoxycytidine & sCD4(soluble recombinant protein); ZALCITABINE [ORANGE BOOK]; GLXC-06578; HMS1548B19; HMS1571O15; HMS2051H18; HMS2090C12; HMS2098O15; HMS2236N08; HMS3261G21; HMS3715O15; Pharmakon1600-01502360; ZALCITABINE [USP IMPURITY]; .beta.-D-2',3'-Dideoxycytidine; Zalcitabine, 2'3'-Dideoxycytidine; Tox21_113491; Tox21_201655; Tox21_303169; Tox21_500360; AC-824; BDBM50145605; EBC-07537; HY-17392R; Lecithinized superoxide dismutase & .beta.-D-2',3'-Dideoxycytidine; NSC759655; s1719; SBB066036; AKOS015854844; AKOS015894505; Tox21_113491_1; CCG-101050; CS-1110; DB00943; LP00360; NC00300; ND06559; NSC-759655; SDCCGSBI-0050348.P002; SRI-7707-13; SRI-7707-14; SRI-7707_15; SRI-7707_17; NCGC00090705-01; NCGC00090705-02; NCGC00090705-03; NCGC00090705-05; NCGC00090705-06; NCGC00090705-07; NCGC00090705-09; NCGC00090705-10; NCGC00090705-11; NCGC00090705-13; NCGC00090705-15; NCGC00090705-24; NCGC00090705-25; NCGC00179242-01; NCGC00257202-01; NCGC00259204-01; NCGC00261045-01; BD164564; BP-58631; HY-17392; ST069364; SY106119; ddC;Dideoxycytidine;2',3'-Dideoxycytidine; 2',3'-Dideoxycytidine & Interferon.alpha.; 2',3'-Dideoxycytidine, >=98% (HPLC); DB-019728; D3581; EU-0100360; NS00005543; SW197364-4; Ro-24-2027-000; C07207; C76390; D00412; EN300-120633; Cytidine, 2',3'-dideoxy- & Interferon.alpha.; F222318; SR-01000075822; SR-01000736919; ZALCITABINE (DIDEOXYCYTIDINE,DDC) [VANDF]; Q2344582; SR-01000075822-1; SR-01000736919-5; BRD-K85925969-001-16-6; BRD-K85925969-001-17-4; Cytidine, 2',3'-dideoxy- & Colony-stimulating factor; Ro-242027000/Ro-24-2027-000; Z1550648753; Zalcitabine, United States Pharmacopeia (USP) Reference Standard; 2 inverted exclamation mark ,3 inverted exclamation mark -Dideoxycytidine; 4-Amino-1-(5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one; 4-Amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2(1H)-one; .beta.-D-2',3'-Dideoxycytidine & Granulocyte-macrophage colony-stimulating factorSynonyms
